News

Arbele Announces Strategic Collaborations on AI Precision Oncology and Manufacturing to Advance CDH17-Targeted Immunotherapeutics

/in , /by

Arbele Announces Strategic Collaborations on AI Precision Oncology and Manufacturing to Advance CDH17-Targeted Immunotherapeutics SEATTLE, Oct. 9, 2024 /PRNewswire/ — Arbele, a leading innovator in biopharmaceutical & biotechnology focused on targeting cadherin-17 (CDH17), is pleased to announce strategic collaborations in precision oncology using artificial intelligence (AI) to advance targeted immunotherapeutics of bispecific T-cell engagers (TCEs) and antibody-drug conjugates […]

Read more

Chime Biologics Successfully Hosts Fuel BioGrowth Chime Day 2024 Event

/in , /by

Chime Biologics Successfully Hosts Fuel BioGrowth Chime Day 2024 Event September 30, 2024, Wuhan – Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, successfully hosted the “Fuel BioGrowth Chime Day” event on September 27 at the East Lake Hotel in Wuhan. The event gathered top key opinion leaders (KOLs) and […]

Read more

Chime Biologics won two awards at the Asia Pacific Biologics CMO Excellence Awards 2024

/in /by

Chime Biologics won two awards at the Asia Pacific Biologics CMO Excellence Awards 2024 Recently, at the 3rd Biologics Contract Manufacturing Asia held in Singapore, Chime Biologics was honored with two prestigious awards at the Asia Pacific Biologics CMO Excellence Awards (APBCEA) 2024 — “Best CDMO Award of the Year” and “Best Biologics CMO Award: […]

Read more

pilot-plant-of-chime-biologics

/in , /by

 pilot-plant-of-chime-biologics No content available

Read more

Going Global – Chime Biologics Embraces Innovation and Quality with Partners

/in , /by

Going Global-Chime Biologics Embraces Innovation and Quality with Partners Foreign biopharmaceutical companies seek CDMO partners with long-term prospects, technology levels, and quality systems aligned with international standards. Jimmy Wei, President of Chime Biologics, highlighted that the company’s competitive edge arises from ensuring product quality, leveraging efficiencies, and maintaining stringent cost controls. July 5, 2024, Shanghai, […]

Read more

Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy

/1 Comment/in , /by

Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy The agreement combines Domain Therapeutics’ candidate DT-7012 with Chime Biologics’ internationally-recognized manufacturing expertise In June 2023, Domain nominated DT-7012, a Treg depleting anti-CCR8 monoclonal antibody (mAb) with best-in-class potential, which enters Phase I studies in 2025 The CCR8 GPCR […]

Read more

Chime Biologics Achieves ISO 27001 Certification to Strengthen Information Security in the CDMO Industry

/in /by

Chime Biologics Achieves ISO 27001 Certification to Strengthen Information Security in the CDMO Industry March 7, 2024, Wuhan, China – Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, today announced that it has obtained ISO/IEC 27001:2022 certification on information security management systems. After passing rigorous reviews on all the items […]

Read more

Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia

/1 Comment/in , /by

Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia Chime Biologics to support the late-stage clinical study and to provide global commercial manufacturing services for Hope Medicine’s first-in-class monoclonal antibody drug, HMI-115. The first-in-class mAb will benefit endometriosis and androgenetic alopecia […]

Read more

Chime Biologics Enters into a Strategic Cooperation Agreement with Korea Kings Pharm to Accelerate the Biosimilar Launch

/in , /by

Chime Biologics Enters into a Strategic Cooperation Agreement with Korea Kings Pharm to Accelerate the Biosimilar Launch Chime Biologics has entered into a strategic collaboration with Kings Pharm for a biosimilar asset, providing cell line development, process development, global GMP manufacturing, commercialization and regulatory filing support. Chime will also supply the commercial production once the […]

Read more

Chime Biologics Announced Global Strategic Cooperation with Panolos Bioscience to Advance Multi-specific Therapeutic Proteins Development

/in , /by

Chime Biologics Announced Global Strategic Cooperation with Panolos Bioscience to Advance Multi-specific Therapeutic Proteins Development Chime Biologics and Panolos Bioscience have entered into a global strategic collaboration agreement on a novel multi-specific protein drug. Chime Biologics will provide development and manufacturing services to Panolos Bioscience for PB203, a next-generation immuno-oncology drug. September 19, Wuhan, China […]

Read more
categoryidArraymk-test